Cambridge, United Kingdom

Sarah Bucknell

This inventor holds 1 USPTO granted patent. Top assignee: Centessa Pharmaceuticals (UK) Limited. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Sarah Bucknell: Innovator in Orexin Receptor Modulation

Introduction

Sarah Bucknell is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of pharmacology, particularly in the development of compounds that modulate orexin receptor activity. Her work is crucial for addressing various disorders linked to orexin receptors.

Latest Patents

Sarah Bucknell holds a patent for "Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists." This patent encompasses compounds of Formula (I′) and their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed are particularly useful for treating disorders such as narcolepsy, hypersomnia, neurodegenerative disorders, and several other health conditions.

Career Highlights

Throughout her career, Sarah has demonstrated a commitment to advancing medical science through her innovative research. She is currently associated with Centessa Pharmaceuticals (UK) Limited, where she continues to explore the therapeutic potential of her discoveries.

Collaborations

Sarah collaborates with esteemed colleagues, including Wojciech Zawodny and Roderick Alan Porter. Their combined expertise enhances the research and development efforts at Centessa Pharmaceuticals.

Conclusion

In summary, Sarah Bucknell is a trailblazer in the field of orexin receptor modulation, with a patent that holds promise for treating various disorders. Her work exemplifies the impact of innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…